Intellectual Property

On January 10, 2025, Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing agreement to commercialize EPYSQLI® (eculizumab-aagh), Samsung’s biosimilar of Soliris®, in the United States.
According to the agreement, Samsung Bioepis will

The America Invents Act (“AIA) provided an accused infringer sued for patent infringement (“Patent Challenger”) with a new, alternative forum to challenge the patents asserted against them: inter partes review (“IPR”). In exchange—and to avoid duplicative parallel district court and

If you’re in a rush, that title is all you need to know.
If you crave explanation, here it is.
One does not “copyright” (verb) one’s work. Copyright rights attach automatically, when sufficiently original works of authorship are fixed in

Intellectual Property Blogs